Daphne Chan, PhD, MHEcon, Head of Dermatology Medical Affairs at Janssen discusses a first-of-its-kind, large-scale clinical study in dermatology 100 percent dedicated to Black, Hispanic, Asian, Indigenous, and other people of color living with moderate to severe plaque psoriasis (PsO). This Phase 3b VISIBLE study was designed to help create a more diverse and equitable clinical research standard, including new approaches to enrollment and retention, broader community engagement, and new data components.
Dr. Chan is currently the Head of Dermatology Medical Affairs at Janssen. She is responsible for leading a team of clinicians and scientists who conduct Phase 3/4 clinical trials designed to address unmet needs in the post-approval setting and contribute insights to inform Phase 2/3 clinical development programs of new investigational therapies. In addition, Dr. Chan’s team is responsible for the development and execution of scientific communications and publications, medical education, and other initiatives intended to increase disease awareness and broaden the communication of new data and evidence that could help inform clinical practice.
Dr. Chan has over 17 years of clinical development and medical affairs experience in the pharmaceutical industry. She has contributed to the clinical development and post-marketing development of various therapies across the Janssen portfolio of therapeutic areas with concentration in dermatology and gastroenterology.
Prior to joining Janssen, Dr. Chan was a research scientist in training at the Hospital for Sick Children and University of Toronto in Canada. She completed her undergraduate training in Human Biology and Toxicology, and her doctoral training in Clinical Pharmacology at the University of Toronto, Canada. In addition, she completed further postgraduate training in Health Economics from the UPF Barcelona School of Management, Spain.